Arsenene-Vanadene nanodots co-activate Apoptosis/Ferroptosis for enhanced chemo-immunotherapy
Source abstract
Abstract
Triple-Negative Breast Cancer (TNBC) represents a highly aggressive subtype of breast cancer with an unfavorable prognosis, characterized by minimal immune infiltration and pronounced immune suppression, resulting in a limited response to immunotherapy. In this study, a multifunctional Arsenene-Vanadene nanodot (AsV) drug delivery system is introduced, which responds to the tumor microenvironment by releasing arsenic and vanadium. Arsenic undergoes oxidation to generate highly toxic trivalent arsenic, which induces apoptosis in tumor cells while utilizing apoptotic cell debris to transiently activate the immune system. Additionally, arsenic binds to cysteine, indirectly facilitating ferroptosis. Concurrently, vanadium's redox cycling properties are harnessed to trigger a Fenton-like reaction, promoting lipid peroxidation. Furthermore, ferroptosis is enhanced through the depletion of glutathione and inactivation of glutathione peroxidase 4 (GPX4), leading to the release of damage-associated molecular patterns and thereby amplifying the anti-tumor immune response. This study represents the first instance of integrating arsenene's apoptosis-inducing properties with vanadium's ferroptosis-enhancing effects, providing a synergistic approach to improving the immunotherapeutic response and offering a potential strategy for enhancing TNBC prognosis. STATEMENT OF SIGNIFICANCE: Triple-negative breast cancer (TNBC) exhibits resistance to immunotherapy due to its highly immunosuppressive tumor microenvironment. In this study, tumour-responsive Arsenene-Vanadene nanodots (AsV) were developed to induce a synergistic effect by triggering apoptosis and ferroptosis through microenvironment-specific mechanisms. The arsenic component generates cytotoxic trivalent arsenic, promoting apoptosis while binding to cysteine, thereby reducing GSH synthesis. Simultaneously, vanadium initiates lipid peroxidation through Fenton-like reactions and disruption of the glutathione/GPX4 axis, further amplifying ferroptotic cell death. This dual-action system transforms tumor cell debris into immune-stimulating signals while circumventing conventional immunotherapy limitations. As the first strategy integrating arsenic-induced apoptosis with vanadium-enhanced ferroptosis, this approach provides a mechanistic framework to overcome TNBC immunosuppression through coordinated cell death pathways, demonstrating potential for precision nanomedicine applications.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Ferroptosis and cancer prognosis · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Cancer statistics, 2022
2. R.S. Zheng, R. Chen, B.F. Han, S.M. Wang, L. Li, K.X. Sun, H.M. Zeng, W.W. Wei, J. He, [Cancer incidence and mortality in China, 2022], Zhonghua Zhong Liu Za Zhi 46(3) (2024) 221–231.
3. Advances in systemic therapies for triple negative breast cancer10.1136/bmj-2022-071674 ↗
4. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer10.1186/s12943-023-01805-y ↗
5. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer10.1038/s41591-021-01323-8 ↗
6. BCRP drives intrinsic chemoresistance in chemotherapy-naive breast cancer brain metastasis10.1126/sciadv.abp9530 ↗
7. Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review
8. Epigenetic mechanisms in breast cancer therapy and resistance10.1038/s41467-021-22024-3 ↗
9. Towards targeting the breast cancer immune microenvironment10.1038/s41568-024-00714-6 ↗
10. Wet chemistry vitrification and metal-to-semiconductor transition of 2D gray arsenene nanoflakes10.1002/adfm.202106529 ↗
11. Arsenene-mediated multiple independently targeted reactive oxygen species burst for cancer therapy10.1038/s41467-021-24961-5 ↗
12. Arsenene: A potential therapeutic agent for acute promyelocytic leukaemia cells by acting on nuclear proteins10.1002/anie.201913675 ↗
13. Anti-Her2 affibody-decorated arsenene nanosheets induce ferroptosis through depleting intracellular GSH to overcome cisplatin resistance10.1186/s12951-023-01963-7 ↗
14. Reduction of dimethylarsenate to highly toxic dimethylarsenite in paddy soil and rice plants10.1021/acs.est.2c07418 ↗
15. In-situ activated arsenic-molybdenum dual-prodrug nanocomplexes for glutathione-depletion enhanced photothermal/chemotherapy against triple-negative breast cancer10.1016/j.cej.2024.155075 ↗
16. Arsenene nanodots with selective killing effects and their low-dose combination with ss-elemene for cancer therapy
17. Apoptosis: a Janus bifrons in T-cell immunotherapy10.1136/jitc-2022-005967 ↗
18. Targeted drug-loaded peptides induce tumor cell apoptosis and immunomodulation to increase antitumor efficacy10.1016/j.bioadv.2024.213852 ↗
19. Two-dimensional nano-biomaterials in regulating the tumor microenvironment for immunotherapy
20. Evoking pyroptosis with nanomaterials for cancer immunotherapy: current boom and novel outlook
21. Tumor microenvironment-responsive delivery nanosystems reverse immunosuppression for enhanced CO gas/immunotherapy10.1002/EXP.20220140 ↗
22. A vacancy-engineering ferroelectric nanomedicine for cuproptosis/apoptosis Co-activated immunotherapy10.1002/adma.202403253 ↗
23. Reactive oxygen species amplifier for apoptosis-ferroptosis mediated high-efficiency radiosensitization of tumors10.1021/acsnano.4c01625 ↗
24. 2D Catalytic nanozyme enables cascade enzyodynamic effect-boosted and Ca(2+) overload-induced synergistic ferroptosis/apoptosis in tumor10.1002/adma.202312316 ↗
25. Ferrostatin-1 loaded Gelatin methacrylate scaffold promotes recovery from spinal cord injury via inhibiting apoptosis and ferroptosis
26. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions10.1016/j.ccell.2024.03.011 ↗
27. Ferroptosis: principles and significance in health and disease10.1186/s13045-024-01564-3 ↗
28. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy
29. Ferroptosis in cancer and cancer immunotherapy10.1002/cac2.12250 ↗
30. Ferroptosis: a double-edged sword mediating immune tolerance of cancer10.1038/s41419-022-05384-6 ↗
31. Recent applications of immunomodulatory biomaterials for disease immunotherapy10.1002/EXP.20210157 ↗
32. Transdermal delivery of interleukin-12 gene targeting dendritic cells enhances the anti-tumour effect of programmed cell death protein 1 monoclonal antibody
33. Vanadium10.1081/CLT-100102425 ↗
34. Metalloptosis:metal ions-induced programmed cell death based on nanomaterials for cancertherapy10.1097/mm9.0000000000000004 ↗
35. Tuning of vanadium valence for value-added recycling and utilization of vanadium from spent selective Catalytic Reduction catalysts10.1016/j.jclepro.2023.136151 ↗
36. A vanadium-based nanoplatform synergizing ferroptotic-like therapy with glucose metabolism intervention for enhanced cancer cell death and antitumor immunity10.1021/acsnano.3c01527 ↗
37. Architecture of vanadium-based MXene dysregulating tumor redox homeostasis for amplified nanozyme catalytic/photothermal therapy10.1002/adma.202307115 ↗
38. Glutathione-activated In situ transformation of nanosized vanadium oxides for Postoperative Precision Tumor Theranostics10.1021/acssuschemeng.3c00298 ↗
39. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance10.1186/s12943-022-01530-y ↗
40. Redox debt leads to metabolic bankruptcy in tumors10.1016/j.trecan.2020.02.012 ↗
41. Involvement of redox signalling in tumour cell dormancy and metastasis10.1007/s10555-022-10077-9 ↗
42. Methylene blue dye test for rapid qualitative detection of hydroxyl radicals formed in a Fenton's reaction aqueous solution10.1021/es0617800 ↗
43. Recent progress in anti-tumor nanodrugs based on tumor microenvironment redox regulation10.1002/smll.202310018 ↗
44. Regulation of ferroptosis by lipid metabolism10.1016/j.tcb.2023.05.003 ↗
45. Regulation of ferroptotic cancer cell death by GPX410.1016/j.cell.2013.12.010 ↗
46. GPX4, ferroptosis, and diseases10.1016/j.biopha.2024.116512 ↗
47. Mitochondrial regulation of ferroptosis10.1083/jcb.202105043 ↗
48. The diversified role of mitochondria in ferroptosis in cancer10.1038/s41419-023-06045-y ↗
49. Ferroptosis: promising approach for cancer and cancer immunotherapy10.1016/j.canlet.2023.216152 ↗
50. Role of IL-6 in dendritic cell functions10.1002/JLB.3MR0621-616RR ↗
51. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells10.1038/s41375-020-01085-1 ↗
52. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic10.1186/s12967-018-1611-7 ↗
53. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer10.1016/j.immuni.2023.01.010 ↗
54. Dendritic cells in cancer immunology and immunotherapy10.1038/s41577-019-0210-z ↗
55. Dendritic cells in cancer immunology10.1038/s41423-021-00741-5 ↗
56. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity10.7150/thno.42243 ↗
57. High mobility group protein B1 decreases surface localization of PD-1 to augment T-cell activation10.1158/2326-6066.CIR-21-0652 ↗